AROG Pharmaceuticals and Mentrik Biotech

5420 LBJ Freeway
Suite 410
Dallas,  TX  75240

United States
http://www.arogpharma.com
  • Booth: 2023

Arog Pharmaceuticals, LLC is developing CRENOLANIB, an orally bioavailable, mutant specific type I inhibitor of receptor kinases FLT3, PDGFRa, and PDGFRb. Crenolanib is currently in phase II development in AML and GIST. Mentrik Biotech, LLC is developing OCARATUZUMAB, an Fc- and Fab-engineered humanized anti-CD20 monoclonal antibody, in B-cell malignancies. Phase II trials in follicular lymphoma have already been conducted in US and Japan with a Phase I trial in rheumatoid arthritis initiated.

Categories

COMPANY TYPE
  • Biotechnology
    • PRODUCT AND SERVICES
  • Monoclonal Antibodies
    • Back to the Search
    Loading ...

    :
    :


    Legend
    Available Timeslot
    Scheduled Appointment
    Personal Appointments
    Request
    Blocked Timeslot
    Restricted Timeslot
    Cancelled
    Declined
     
    Reserve a Booth Exhibitor Login Sponsor ASH News TV

    Have a Question?
    Call 888-273-5704

    International callers dial
    001 703-449-6418

    Monday - Friday
    9 a.m. - 5 p.m.
    Eastern Time

    Contact us
      • ASH Exposition Management
      • SPARGO, Inc.
      • Toll Free: (800) 564-4220
      • Phone: (703) 631-6200
      • Fax: (703) 563-2691
      • Email: ashexhibits@spargoinc.com